sequencing (1 site) Conference 24 countries in RAS- mutation Survey of 96 Survey took Included FFPE Boleij 2015 3,972 patients Various TATO abstract Europe testing in mCRC pathology place Oct tissue; not laboratories 2014-Dec specified undertaking 2014 whether RAS testing in testing was on clinical practice newly in Europe; acquired, information archive tissue provided on or either approximately 20-30 of the most recent tested mCRC patients Lievre 2015 Conference France KRAS mutation Observational 375 patients Mar Not specified Not specified TATO abstract testing in mCRC multi-centre June 2014 whether Flash-RAS study retrospective testing was on study of RAS newly testing in mCRC acquired, in clinical archive tissue practice; 104 or either centres Lowe 2016 Conference US KRAS, NRAS Retrospective 1550 patients Diagnosed Not specified Not specified TATO abstract and BRAF review of testing between Jan whether mutation testing in community 2011-Aug testing was on in mCRC cancer centres 2015 newly (OSCER acquired, database) archive tissue or either Gracia 2011 Conference Spain EGFR mutation Prospective 1009 patients 6-month study; Various Biopsy and TATO abstract testing in epidemiological with available date not cytological Test failures study to gain sample reported sample; not NSCLC insight into specified variables that whether affect the testing was on
sequencing (1 site) Boleij 2015 Conference abstract 24 countries in Europe RAS- mutation testing in mCRC Survey of 96 pathology laboratories undertaking RAS testing in clinical practice in Europe; information provided on approximately 20-30 of the most recent tested mCRC patients 3,972 patients Survey took place Oct 2014-Dec 2014 Various Included FFPE tissue; not specified whether testing was on newly acquired, archive tissue or either TATO Lievre 2015 Flash-RAS study Conference abstract France KRAS mutation testing in mCRC Observational multi-centre retrospective study of RAS testing in mCRC in clinical practice; 104 centres 375 patients Mar 2014 Not specified Not specified whether testing was on newly acquired, archive tissue or either TATO Lowe 2016 Conference abstract US KRAS, NRAS and BRAF mutation testing in mCRC Retrospective review of testing in community cancer centres (OSCER database) 1550 patients Diagnosed between Jan 2011-Aug 2015 Not specified Not specified whether testing was on newly acquired, archive tissue or either TATO Gracia 2011 Conference abstract Spain EGFR mutation testing in NSCLC Prospective epidemiological study to gain insight into variables that affect the 1009 patients with available sample 6-month study; date not reported Various Biopsy and cytological sample; not specified whether testing was on TATO Test failures June
1331-Contracted_Assessment_Report-accessible.docx